Table 3.

Costs, effectiveness, and ICERs of the treatments over a 2-year horizon

Attribute	Statistic	ComboRx		Rezūm®	UroLift®	Prostiva®	Greenlight®	TURP
		MedicarePart D price	Branded price
Cost	Mean at 2 years	$1,736	$7,082	$2,582	$6,386	$2,855	$5,099	$5,181
IPSS	Mean at 2 years	18.9	18.9	10.2	11.4	10.9	7.4	6.4
Cost-effectiveness of Rezūm versus othera	ICER at 2 years	$97	−$518	Base comparator	−$3,058	−$352	$900	$686
	Dominated	No	Yes	NA	Yes	Yesb	No	No
Cost-effectiveness of TURP versus othera	ICER at 2 years	$276	−$1,523	$6,863	−$240	$509	$83	Base comparator
	Dominated	No	Yes	No	Yes	No	No	NA

Notes: “Dominated” indicates a treatment that is more expensive and less effective than another is dominated by the other. ICER: cost per additional point reduction (in IPSS) provided by the more expensive treatment. Bolded, negative numbers indicate higher cost.

^aOver 2-year time horizon with both costs and effects discounted at 3% annually.

^bThe mean IPSS and costs indicate dominance, but the effectiveness and costs are not dissimilar when uncertainty is considered. Costs based on US$.

Abbreviations: ComboRx, combination prescription drug therapy; Greenlight PVP, photovaporization of the prostate; ICER, incremental cost-effectiveness ratio; IPSS, International Prostate Symptom Score; NA, not applicable; Prostiva, conductive radiofrequency thermal therapy; Rezūm, convective radiofrequency water vapor thermal therapy; TURP, transurethral resection of the prostate; UroLift, prostatic urethral lift.